Symbol="ARDS"
AssetType="Common Stock"
Name="Aridis Pharmaceuticals Inc"
Description="Aridis Pharmaceuticals, Inc., an advanced-stage biopharmaceutical company, is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company is headquartered in Los Gatos, California."
CIK="1614067"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="5941 OPTICAL COURT, SAN JOSE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="9205000"
EBITDA="-28162000"
PERatio="None"
PEGRatio="None"
BookValue="-0.773"
DividendPerShare="0"
DividendYield="0"
EPS="-1.66"
RevenuePerShareTTM="0.136"
ProfitMargin="0"
OperatingMarginTTM="-9.58"
ReturnOnAssetsTTM="-1.075"
ReturnOnEquityTTM="0"
RevenueTTM="2986000"
GrossProfitTTM="-22605000"
DilutedEPSTTM="-1.66"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.088"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="2.061"
PriceToSalesRatioTTM="7.33"
PriceToBookRatio="5.4"
EVToRevenue="17.57"
EVToEBITDA="-1.248"
Beta="0.783"
num_52WeekHigh="2.77"
num_52WeekLow="0.15"
num_50DayMovingAverage="0.228"
num_200DayMovingAverage="0.653"
SharesOutstanding="36240300"
DividendDate="None"
ExDividendDate="None"
symbol="ARDS"
open="0.25"
high="0.27"
low="0.24"
price="0.26"
volume="303816.00"
latest_trading_day="2023-07-10"
previous_close="0.25"
change="0.01"
change_percent="3.3858%"
aroon_positive_momentum_days="21"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="2666745"
Change_recent_avg="0.01"
Delta_recent_avg="0.03"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.34"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="491"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0114.jpeg"
image_negative_thumbnail_id_2="160"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0016.jpeg"
image_neutral_thumbnail_id_1="589"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_neutral_thumbnail_id_2="522"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0077.jpeg"
image_positive_thumbnail_id_1="997"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0159.jpeg"
image_positive_thumbnail_id_2="639"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0069.jpeg"
image_professor_thumbnail_id_1="1186"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
image_professor_thumbnail_id_2="1173"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
